Latest news with #ISPOR2025
Arab News
a day ago
- Business
- Arab News
Lean strengthens its global footprint with scientific achievements, strategic partnerships
Lean Business Services — the Kingdom's foremost developer of digital-health solutions and a Public Investment Fund portfolio company— continues to consolidate its leadership in the digital-health sector at both national and international levels. At ISPOR 2025 in Montréal, Canada, the company's research team presented three peer-reviewed studies grounded in advanced analytics and extensive national datasets before embarking on an official visit to South Korea to explore collaborations in health technology and research. The first study introduced an integrated economic model that assesses the cost-effectiveness of Type 2 diabetes-prevention programs over a 10-year horizon, capturing both direct and indirect costs from the first-year diagnosis through long-term complications. A second paper provided a comprehensive assessment to date of Saudi Arabia's chronic disease burden, leveraging records from more than 33 million individuals and sophisticated statistical models to inform resource allocation and healthcare planning. The third study delivered a five-year review of more than 2 million psychotropic prescriptions, pinpointing opportunities to refine prescribing practices, particularly for older adults, relative to other chronic-medication regimens. To broaden its international collaboration, a Lean delegation traveled to South Korea, where it joined the Saudi–Korean Business & Investment Forum, met leading health-tech institutions, and examined best practices at Seoul National University Hospital. Discussions focused on artificial intelligence, biotechnology, and population data analytics. Engineer Mohannad Al-Rasheed, Lean's chief executive officer, expressed pride in representing the Kingdom on these global stages. 'Lean is committed to building knowledge partnerships that elevate Saudi Arabia as an advanced hub for digital health,' he said. 'Our active participation in specialized international gatherings reflects the maturity of the Saudi health sector and its ability to export both expertise and solutions.' Driven by the conviction that data-powered innovation is key to a more efficient and inclusive healthcare future, Lean will continue to invest in research and cross-border collaboration, supporting Vision 2030's goal of a cutting-edge, sustainable digital-health ecosystem for the Kingdom.
Associated Press
13-05-2025
- Business
- Associated Press
OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the Datavant Connect platform to accelerate healthcare data discovery, analytics, and partner assessment processes. These new advancements will be presented by Datavant this week at ISPOR 2025, highlighting the importance of secure, scalable, and fit-for-purpose data solutions in driving innovation across healthcare and life sciences. The healthcare industry has experienced a tremendous volume of health-related data generation—extending beyond patient interactions to include genomic sequencing, biomarker data, and more. In many ways, data has become the new oil, holding immense value for clinical and scientific advancement. However, like crude oil, this raw data must be refined—its fragmented and siloed nature continues to hinder accessibility and usability. As healthcare and life sciences organizations increasingly seek targeted, fit-for-purpose datasets, scalable and secure technological solutions have become essential to unlocking its full potential. Leveraging AWS Clean Rooms, OneMedNet will offer sophisticated data partner assessment and discovery tools through the Datavant Connect platform, enabling secure collaboration environments without direct data movement or sharing of raw data. This 'no underlying data movement' approach significantly enhances data security and privacy, allowing for effective feasibility analyses between data sources and buyers. These advancements facilitate faster identification and evaluation of relevant healthcare datasets, directly addressing the industry's strategic, privacy, and data handling challenges. By empowering healthcare organizations with precise, secure, and efficient data access, OneMedNet accelerates the generation of valuable insights and transformative outcomes. 'Much of today's healthcare data remains untapped due to complexity and interoperability issues,' continued Aaron Green. 'Datavant Connect powered by AWS Clean Rooms effectively removes these barriers, positioning OneMedNet as an indispensable partner for organizations aiming to fully harness the potential of healthcare data.' About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. OneMedNet Contacts: Michael Wong, VP Marketing Email: [email protected] SOURCE: ONEMEDNET CORPORATION
Yahoo
13-05-2025
- Business
- Yahoo
OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the Datavant Connect platform to accelerate healthcare data discovery, analytics, and partner assessment processes. These new advancements will be presented by Datavant this week at ISPOR 2025, highlighting the importance of secure, scalable, and fit-for-purpose data solutions in driving innovation across healthcare and life sciences. The healthcare industry has experienced a tremendous volume of health-related data generation—extending beyond patient interactions to include genomic sequencing, biomarker data, and more. In many ways, data has become the new oil, holding immense value for clinical and scientific advancement. However, like crude oil, this raw data must be refined—its fragmented and siloed nature continues to hinder accessibility and usability. As healthcare and life sciences organizations increasingly seek targeted, fit-for-purpose datasets, scalable and secure technological solutions have become essential to unlocking its full potential. Leveraging AWS Clean Rooms, OneMedNet will offer sophisticated data partner assessment and discovery tools through the Datavant Connect platform, enabling secure collaboration environments without direct data movement or sharing of raw data. This 'no underlying data movement' approach significantly enhances data security and privacy, allowing for effective feasibility analyses between data sources and buyers. These advancements facilitate faster identification and evaluation of relevant healthcare datasets, directly addressing the industry's strategic, privacy, and data handling challenges. By empowering healthcare organizations with precise, secure, and efficient data access, OneMedNet accelerates the generation of valuable insights and transformative outcomes. "Much of today's healthcare data remains untapped due to complexity and interoperability issues," continued Aaron Green. "Datavant Connect powered by AWS Clean Rooms effectively removes these barriers, positioning OneMedNet as an indispensable partner for organizations aiming to fully harness the potential of healthcare data." About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. OneMedNet Contacts: Michael Wong, VP Marketing Email: SOURCE: ONEMEDNET CORPORATIONError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
Projected economic benefits of using AI-powered detection/diagnostic Software as a Medical Device, like eyonis® LCS, will be presented at ISPOR 2025, the annual conference of the leading professional society for health economics and outcomes research Positive eyonis® LCS' REALITY pivotal data to be presented at American Thoracic Society (ATS) 2025 International Conference The eyonis® team will be hosting interested parties at booth #1662 during ATS 2025 SOPHIA ANTIPOLIS, France, May 12, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will attend two major health conferences and present posters on its Software as a Medical Device (SaMD) eyonis® LCS, for Lung Cancer Screening. The eyonis® LCS SaMD is an AI-powered Software as a Medical Device (SaMD) to detect and diagnose (CADe/CADx) lung cancer in Low Dose Computed Tomography (LDCT) images. eyonis® LCS has met the primary endpoints in the two pivotal clinical trials required for FDA and CE marking regulatory submissions. The FDA 510K application for eyonis® LCS U.S. marketing authorization is scheduled for submission shortly and clearance and commercialization are expected late this year. Median will present its findings on the projected U.S. economic benefit that eyonis® LCS can offer payers at ISPOR 2025, the leading conference for health economics and outcomes research, taking place in Montreal, QC, Canada, May 13-16, 2025. Based on a Markov health economic model simulating lung cancer progression over five years, the analysis, grounded in the respective performance of radiologists and AI, demonstrates that eyonis® LCS enhances early detection and characterization, reduces unnecessary procedures, and generates significant cost savings for U.S. payers. These findings support integrating eyonis® LCS into routine lung cancer screening programs. Separately, at the American Thoracic Society (ATS) International Conference, in San Francisco, CA, USA, from May 17-21, 2025, Median will present positive data from the pivotal trial REALITY showing that eyonis® LCS optimized detection, localization, characterization and management of small screening-detected nodules, leading to earlier diagnoses, more effective treatment and positively impacting survival of lung cancer patients. In addition, the Median eyonis® team will welcome interested parties during ATS 2025 at Booth #1662. The Company will share the latest developments for eyonis® LCS SaMD. Presentation at the ISPOR 2025 Conference - Montreal, QC, Canada, May 13-16, 2025 Poster #OP9: Budget Impact Model of Enhanced Lung Cancer Screening with AI/ML Tech-Based Software as a Medical Device (SaMD) on a US Cohort and Private Payer Perspective Poster Session 5Topic: Organizational PracticesFriday May 16, 2025, 9:00 am - 11:30 am EDTPoster discussion slot from 9:00 to 10:00 am EDTMain Poster AreaFirst author & presenter: Antoine Disset, PhD, VP Market Access and Gov. Affairs eyonis®, Median Technologies Presentation at the American Thoracic Society (ATS) 2025 International Conference – San Francisco, CA, USA – May 17-21, 2025. Poster #13190: AI-Assisted Lung Cancer Screening: Results from REALITY, a Pivotal Validation Study of an AI/ML-Based Software Poster Session: B110 - The road to Early Detection: Advancing Lung Cancer Screening through AI, Risk Models, and Real-World DataTopic: Lung Cancer, Thoracic OncologyPoster discussion: Monday May 19, 2025, 2:15 pm - 4:15 pm PDTMain Poster Area – Poster Board #616 About eyonis® LCS: eyonis® Lung Cancer Screening (LCS) is an artificial intelligence AI/ML-based computer aided detection and diagnosis (CADe/CADx) system, or Software as a Medical Device (SaMD) that uses machine learning to help analyze imaging data generated with low dose computed tomography (LDCT) to aid radiologists in diagnosis of lung cancer at the earliest stages, when it can still be cured in many patients. eyonis® LCS is the subject of two pivotal studies required for marketing approvals in the U.S. and Europe: REALITY ( ID: NCT06576232) and RELIVE ( ID: NCT06751576), both of which have been successfully completed. Regulatory filings including this pivotal data are scheduled to be submitted for FDA 510(k) clearance and CE marking in May and June 2025 respectively. About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit Forward-Looking Statements This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates, as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance. These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers. View source version on Contacts MEDIAN TECHNOLOGIESEmmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 Investors - SEITOSEI ACTIFINGhislaine Gasparetto+33 6 21 10 49 U.S. media & investors - COHESION BUREAUChris Maggos+41 79 367 Press – ULYSSE COMMUNICATIONBruno Arabian+33 6 87 88 47 26barabian@ Nicolas Entz+33 6 33 67 31 54nentz@
National Post
08-05-2025
- Health
- National Post
OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025
Article content Article content What: OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1's Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI). Consistent with other findings and despite warnings on the label, there was no significant increase in SI prevalence after GLP-1 initiation. Article content When: The poster session will be held at ISPOR 2025 on Wednesday, May 14, from 4:00 – 7:00 PM, with a discussion period from 6:00 – 7:00 PM. Article content Key Findings: Amid growing scrutiny of GLP-1 receptor agonists (used in diabetes and obesity), OM1's real-world study finds no significant change in suicidal ideation (SI) following treatment initiation across both therapeutic populations. Article content Why It Matters: GLP-1s indicated for obesity feature a package label warning for suicidal ideation, whereas those indicated for diabetes do not. This research adds to the growing body of evidence exploring whether this warning may present an unnecessary obstacle to treatment and a potential barrier to equitable access to healthcare for a long stigmatized population. Article content Suicidal ideation is often undercoded or missing entirely in claims-based datasets. By applying natural language processing (NLP) to unstructured clinician notes, OM1's study captures a richer, more nuanced view of patient mental health. This study reinforces the role of AI and real-world data (RWD) in advancing pharmacovigilance and public health safety. Article content About OM1: OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE. Article content Article content Article content Article content Article content Contacts Article content Article content
